Navigation Links
Par Pharmaceutical Reports First Quarter 2008 Results
Date:5/8/2008

period in 2007 primarily due to competitive pressures in the following products: fluticasone, propranolol, various amoxicillin products, tramadol HCl and acetaminophen tablets, glyburide/metformin, cabergoline, ranitidine syrup, as well as lower royalties. Partially offsetting these decreases were increased sales of metoprolol resulting from the launch of additional strengths in the third quarter of 2007.

Par's first quarter gross margin was 32.0% of total revenues compared to 37.4% in 2007. The decrease in the Company's gross margin resulted primarily from the non-recurrence of the 2007 launch of propranolol and decreased sales of certain existing generic products and lower royalty income both resulting from competitive pressure, tempered by higher gross margin contribution from Strativa's net sales of Megace(R) ES.

Research and development (R&D) expenses increased 22.2% for the first quarter 2008 compared with the first quarter 2007, which was primarily attributed to the initial $5.0 million payment to Alfacell Corporation for an exclusive licensing agreement to acquire the commercialization rights to ONCONASE(R).

Selling, general and administrative (SG&A) expenses for the first quarter 2008 decreased 3.7% from first quarter 2007. The decrease is due to lower expenses related to the sales and marketing of Megace(R) ES, lower finance and accounting costs, and lower stock-based compensation employment costs.

During the first quarter of 2008, the Company recognized a gain on the sale of product rights of $1.0 million related to the sale of two non-core ANDAs. In addition, the Company recognized a gain of $0.6 million related to providing certain information and other deliverables related to Megace(R) ES to a third party that is seeking to commercialize Megace(R) ES outside of the U.S..

Year-to-date Accomplishments

Patrick G. LePore, chairman, president and chief executive officer, states, "2008 is the year to execute on our s
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. Vion Pharmaceuticals to Appeal Nasdaq Delisting
2. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
3. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
4. Par Pharmaceutical Acquires Spectrum Pharmaceuticals Interest In Sumatriptan Injection
5. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
6. Cadient Group Continues Winning Streak; Receives Multiple Honors at 2008 Pharmaceutical Advertising and Marketing Excellence Awards
7. Alseres Pharmaceuticals, Inc. to Present at The Neurotech Industry Investing & Partnering Conference
8. Par Pharmaceutical to Host First Quarter 2008 Earnings Conference Call on May 9 at 9:00 AM
9. ADVENTRX Pharmaceuticals to Report First Quarter 2008 Results
10. BioCryst Pharmaceuticals to Announce First Quarter 2008 Financial Results on May 8, 2008
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... December 24, 2014 The federal ... allege the blood thinner caused life-threatening episodes of ... leadership structure for the proceeding, Bernstein Liebhard LLP ... the Court plans to select lawyers to serve ... plans on appointing a Plaintiffs’ Steering Committee, which ...
(Date:12/24/2014)... 25, 2014 The report “Stivarga (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is a drug which is used in the treatment ... administered and is also prescribed to patients who suffer ... FDA approved is a multi-kinase inhibitor and it blocks ...
(Date:12/24/2014)... HealthDay Reporter TUESDAY, Dec. 23, 2014 (HealthDay News) -- ... year will be allowed to donate blood in the United States, ... on donations from men who have sex with men. The ... a new draft guidance in early 2015 that would ultimately open ... is changing its policy based on data from other countries that ...
(Date:12/24/2014)... -- A new, injectable weight-loss drug has been approved ... agency on Tuesday approved Saxenda (liraglutide) for adults who ... have at least one weight-related health condition, such as ... Patients taking the drug, made by Novo Nordisk, ... the FDA noted. "Obesity is a public health ...
Breaking Medicine News(10 mins):Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Stivarga Colorectal Cancer Treatment Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:FDA Approves New Weight-Loss Drug 2Health News:FDA Approves New Weight-Loss Drug 3
... by Massachusetts General Hospital (MGH) researchers to shield the ... radiation and chemotherapy has passed an important milestone. ... Sciences University (OHSU), published online in the journal Fertility ... to an FDA-approved agent called FTY720 preserved the fertility ...
... Reinberg HealthDay Reporter , MONDAY, Feb. 21 (HealthDay ... to 59 struggle with some kind of hearing loss, and ... older, a new study says. Yet much of that ... , Factors that contribute to hearing loss include working in ...
... high volume of mammograms may not detect more cancers but ... according to a new study published online and in the ... our expectations, we observed no clear association between volume and ... M.P.H., senior investigator at the Group Health Research Institute in ...
... This release is available in French . ... in your spit could reveal if you,re on the point ... and Robert-Paul Juster of the Centre for Studies on Human ... In addition to professional and personal suffering, burnout puts distressed ...
... medical errors isn,t quite as new as it seems. A ... at the turn of the last century, has turned up ... his suggestions for preventing those mistakes in the future. ... of Surgery , suggest that such open documentation may have ...
... , MONDAY, Feb. 21 (HealthDay News) -- Educating ... helps increase rates of skin self-examination and follow-up with ... States, an estimated 100,000 living kidney transplant recipients are ... tumors occurring in the skin that can spread to ...
Cached Medicine News:Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 2Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 3Health News:Protective strategy shields primate ovaries from radiation-therapy-induced damage 4Health News:Hearing Loss Common Among Middle-Aged Adults: Study 2Health News:Hearing Loss Common Among Middle-Aged Adults: Study 3Health News:Higher volume reduces false positives in screening mammography 2Health News:Simple spit and blood tests might detect burnout before it happens 2Health News:Simple spit and blood tests might detect burnout before it happens 3Health News:Famed neurosurgeon's century-old notes reveal 'modern' style admission of medical error 2Health News:Education Might Help Kidney Recipients Spot Skin Cancer 2
(Date:12/24/2014)... /PRNewswire/  -- Tianyin Pharmaceutical Inc. (NYSE Amex: ... in the patented biopharmaceutical, modernized traditional Chinese medicine ... released unaudited preliminary financial results for the first ... Year 2015 Ended September 30, 2014 Financial Highlights: ... $14.7 million in 1Q14 with gross margins improved ...
(Date:12/24/2014)...  Diplomat Pharmacy, Inc. (NYSE: DPLO ), ... announce Jennifer Hagerman , Pharm.D., AE-C, senior director ... as the president of the Michigan Pharmacists Association on ... place Feb. 28, 2015, at the MPA Annual Convention ... Center in Detroit, Michigan . Hagerman ...
(Date:12/24/2014)... KENNEWICK, Wash. , Dec. 23, 2014 /PRNewswire/ ... stage development company engaged primarily in the development ... and therapeutic applications, today announced that it has ... the Food and Drug Administration ("FDA") for marketing ... to Section 513(f)(2) of the U.S. Food, Drug ...
Breaking Medicine Technology:TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 2TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 3TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 4TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 5TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 6TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 7TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 8TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 9TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 10TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 11TPI Presents Unaudited Preliminary First Quarter Fiscal Year 2015 Financial Results 12Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3
... Solutions, Inc. (NYSE: MHS ) announced today ... principal amount of 2.750% senior notes due September 15, ... senior notes due September 15, 2020 in an underwritten ... & Co. are acting as representatives of the several ...
... Inc. (Nasdaq: CADX ), a biopharmaceutical ... product candidates principally for use in the hospital ... a corporate overview at the following investment conferences: ... Global Healthcare ConferenceDate:  Tuesday, September 14, 2010 Time: ...
Cached Medicine Technology:Medco Issues $1.0 Billion of Senior Notes 2Medco Issues $1.0 Billion of Senior Notes 3Cadence Pharmaceuticals to Present at Four Investment Conferences During the Month of September 2010 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: